Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno Studio Clinico Randomizzato e Controllato per Valutare l'Efficacia di Informazioni Personalizzate per il Paziente e Follow-up Digitale Ambulatoriale Gestito Volontariamente dal Paziente (I-POD) come Adiuvante al Trattamento Standard Secondo le Linee Guida Nazionali NTP tra i Pazienti Adulti con Trauma in Norvegia. (POSTRAUMA)

10 novembre 2026 aggiornato da: Haukeland University Hospital

Uno Studio Clinico Randomizzato e Controllato per Valutare l'Efficacia di Informazioni Personalizzate per il Paziente e di un Follow-Up Ambulatoriale Digitale Volontario Gestito dal Paziente come Integrazione al Trattamento Standard Secondo le Linee Guida Nazionali in Pazienti Adulti con Trauma in Norvegia (Lo Studio POSTRAUMA).

The POSTRAUMA trial is a clinical trial at The Regional trauma centre of Western Norway, Haukeland University Hospital.

Trauma is the leading cause of death worldwide in patients aged 1-45 years. In Norway, approximately 10,000 patients are admitted to hospital annually due to trauma, with 66% being male. The mean age is 43 years for male and 48 years for female, indicating a relatively young patient population.

While mortality rates are decreasing, a significant proportion of trauma survivors experience long-term disabilities, reduced quality of life, and difficulties in returning to work. These consequences impose substantial burdens on individuals, families, and society. Considering these issues, a shift in focus is needed-from survival alone to long-term functional recovery and quality of life after trauma.

Severe trauma often requires long-term follow-up, both physically and psychosocially. Traditional follow-up can be fragmented and not tailored to individual needs. Digital patient monitoring and tailored information have the potential to improve patient pathways, but knowledge about how these are experienced by patients is limited.

The goal is to find out if Norwegian trauma patients who receive tailored patient information and patient-managed outpatient digital follow-up, in addition to standard treatment have:

  • Less disability
  • Return more often to work
  • Improved quality of life

The study population are Norwegian trauma patients, 16 years or older at date of inclusion, who are admitted to Haukeland University hospital (HUS) following trauma with trauma team activation. 256 patients will be included in this trial.

Participants will:

  • Answer a questionnaire at inclusion, one month, 6 months and 12 months.
  • Participants in the intervention group will be invited to digital outpatient follow up one month after the accident.
  • Some participants will be interviewed about how they experienced their trauma follow up.

Panoramica dello studio

Descrizione dettagliata

Trauma is the leading cause of death worldwide in patients aged 1-45 years. Injuries and violence contribute to approximately 10% of all disability-adjusted life years globally. In Norway, approximately 10,000 patients are admitted to hospital annually due to trauma, with 66% being male. The mean age is 43 years for male and 48 years for female, indicating a relatively young patient population compared to other medical cohorts. The socioeconomic and functional implications of trauma are significant. With the expected demographic shift toward an aging population in Norway, the incidence of trauma among older adults is also expected to increase, placing greater demands on in-hospital trauma and rehabilitation services. Socioeconomic status, gender and age have been identified as key predictors of long-term outcomes following trauma, with female and individuals with lower education levels or ongoing compensation claims often reporting poorer outcomes.

While mortality rates are decreasing due to advancements in trauma systems, prevention strategies and medical care, a significant proportion of trauma survivors experience longterm disabilities, reduced quality of life, and difficulties in returning to work. These consequences impose substantial burdens on individuals, families, and society. Considering these issues, a shift in focus is needed-from survival alone to long-term functional recovery and quality of life after trauma.

Severe trauma often requires long-term follow-up, both physically and psychosocially. Traditional follow-up is often fragmented and not tailored to individual needs. Digital patient monitoring and tailored information have the potential to improve patient pathways, but knowledge about how these are experienced by patients, relatives, and healthcare professionals is limited.

This study aims to investigate how early rehabilitation and patient-centred care pathways can improve short and long-term outcomes for trauma patients. The objectives of the POSTRAUMA-trial is to assess the efficacy of a tailored patient information and patient managed outpatient digital follow-up (I-POD), as an adjunct to standard treatment according to the national guidelines in the National Trauma Plan (NTP) among adult trauma patients in Norway. The main research question is whether participants in the intervention group have less disability and improved health-related quality of life 6 months after the accident compared to the control group which receives standard treatment alone?

The latter part of the trial is a qualitative study which will follow the consolidated criteria for reporting qualitative studies (COREQ). SI will through in-dept and semi-structured interviews explore the participants experiences following trauma in general, and more specific to evaluate how the written patient information and digital follow-up was perceived. The SI will encourage the participants to talk about issues regarding this by asking open-ended questions in one-to-one interviews. The illness trajectory framework will be used as a theoretical framework, along with the WHOs International Classification of Functioning, Disability and Health (ICF) to ensure that preinjury, physical and biopsychosocial factors are evaluated.

Tipo di studio

Interventistico

Iscrizione (Stimato)

256

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

      • Bergen, Norvegia, 5021
        • Surgical Department, Haukeland University hospital
        • Contatto:
        • Contatto:
        • Sub-investigatore:
          • Marianne Wesnes, Cand.med
        • Investigatore principale:
          • Geir Arne Sunde, Ph.d

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

16 anni e precedenti (Bambino, Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • 16 years or older
  • Fulfils the national criteria for TTA and admitted to HUS following trauma
  • Included in NTR database
  • Able to give informed consent

Exclusion Criteria:

  • 15 years or younger
  • Not included in NTR database
  • Deceased before discharge from the hospital.
  • Not able to give informed consent
  • Insufficient command of the Norwegian language
  • Foreign tourists or nationals
  • Suicide attempt or serious self-inflicted trauma
  • Serious psychiatric disorders or serious ongoing substance abuse

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Nessun intervento: Control group

Standard treatment and follow up after trauma according to national guidelines in the National trauma plan.

Comparatore attivo: Intervention group

Tailored patient information and patient-managed outpatient follow up as an adjunct to standard treatment according to national guidelines in the National trauma plan

The objective of the POSTRAUMA-trial is to assess if the I-POD intervention combined with standard treatment according to national guidelines, lead to less disability measured by EQ5D-index, better health-related quality of life measured by EQ-VAS and increased return to studies and work compared to standard treatment after trauma.

Altri nomi:
  • intervento I-POD

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
EuroQol five-dimension utility score (EQ5D-index) from baseline to 6 months after the trauma in both groups.
Lasso di tempo: From baseline to 6 months after the trauma

The primary objective is to assess the efficacy of the I-POD-intervention as an adjunct to standard treatment after trauma according to national guidelines in adult patients in Norway. The efficacy is measured as the primary endpoint: EuroQol five-dimension utility score (EQ5D-index) from baseline to 6 months after the trauma in both groups. EQ5D-index ranges from - 0,59 (worst score) to 1 (perfect health, best score). 0 equals death. Baseline is defined as the time of inclusion.

The I-POD intervention is a tailored patient Information and Patient-managed Outpatient Digital follow-up treatment.

From baseline to 6 months after the trauma

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Differenze nel Ritorno al lavoro (RTW) tra il gruppo di controllo e il gruppo di intervento a 1 mese, 6 mesi e 12 mesi dopo il trauma secondo i dati riportati dal paziente a 1 mese, e a 6 mesi e 12 mesi secondo i dati NTR misurati con variabili dicotomiche (sì/no)
Lasso di tempo: Baseline a 1 mese, 6 mesi e 12 mesi
Baseline a 1 mese, 6 mesi e 12 mesi
Differences in EuroQol five-dimension utility score (EQ5D-index) between the control group and the intervention group from baseline to 1 month and 12 months after the trauma.
Lasso di tempo: Baseline to 1 month and 12 months after the trauma

EQ5D-index ranges from - 0,59 (worst score) to 1 (perfect health, best score). 0 equals death.

Baseline to 1 month and 12 months after the trauma
Differences in HRQoL between the control group and the intervention group from baseline to 1 month, 6 months and 12 months after the trauma, measured by EuroQol visual analogue scale (EQ-VAS).
Lasso di tempo: Baseline to 1 month, 6 months and 12 months after the trauma

The EQ-VAS (EuroQol Visual Analogue Scale) is a standard tool used with the EQ-5D health questionnaire to measure a person's self-rated overall health on a vertical scale from 0 (worst imaginable health) to 100 (best imaginable health).

Baseline to 1 month, 6 months and 12 months after the trauma

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Geir Arne Sunde, Ph.d, Haukeland University hospital, Surgical Department

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 dicembre 2026

Completamento primario (Stimato)

1 dicembre 2027

Completamento dello studio (Stimato)

31 dicembre 2029

Date di iscrizione allo studio

Primo inviato

25 novembre 2025

Primo inviato che soddisfa i criteri di controllo qualità

25 novembre 2025

Primo Inserito (Effettivo)

8 dicembre 2025

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

12 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

10 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • 909877

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

Sharing of privacy data is not within the scope of the ethical approval granted by REK West.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi